natgillin/translations-raw huggingface dataset:
Liprolog Mix, Liprolog Basal and Liprolog 200 units/ml should never be given into a vein.
Zdravil Liprolog Mix, Liprolog Basal in Liprolog 200 enot/ml se ne sme dajati v veno.
How has Liprolog been studied?
Kako je bilo zdravilo Liprolog raziskano?
Liprolog is supplied in vials, cartridges and prefilled pens (Liprolog KwikPen).
Na voljo je v vialah, vložkih ali napolnjenih injekcijskih peresnikih (Liprolog KwikPen).
Liprolog, Liprolog Basal and Liprolog Mix may be given by injection under the skin of the upper arm, thigh, buttock or abdomen (tummy).
Zdravila Liprolog, Liprolog Basal in Liprolog Mix se dajejo pod kožo z injekcijo v nadlaket, stegno, zadnjico ali trebuh.
What is Liprolog?
Kaj je zdravilo Liprolog?
What is Liprolog used for?
Za kaj se zdravilo Liprolog uporablja?
Liprolog contains the active substance insulin lispro.
Zdravilo Liprolog vsebuje zdravilno učinkovino insulin lispro.
How is Liprolog used?
Kako se zdravilo Liprolog uporablja?
How does Liprolog work?
Kako zdravilo Liprolog deluje?
It can also be used on its own in:
Uporablja se lahko tudi samostojno pri:
This was converted into a full marketing authorisation on 20 November 2018.
To je bilo 20. novembra 2018 spremenjeno v običajno dovoljenje za promet.
Further information on Venclyxto can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Venclyxto.
Nadaljnje informacije o zdravilu Venclyxto so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Venclyxto.
Regarding safety, the medicine's side effects are considered acceptable.
Kar zadeva varnost, neželeni učinki zdravila veljajo za sprejemljive.
The starting dose is 20 mg daily and the dose is gradually increased over 5 weeks to 400 mg.
Začetni odmerek je 20 mg na dan, ta pa se v obdobju pet tednov postopoma povečuje do 400 mg.
Although there is a risk of tumour lysis syndrome, a complication that occurs when the cancer cells are being destroyed too quickly, this risk can be contained through preventive measures, such as increasing the dose gradually or reducing the dose, if needed.
Čeprav obstaja tveganje za sindrom tumorske lize, tj. zaplet, ki se pojavi, kadar se rakave celice prehitro uničujejo, se to tveganje lahko obvlada s preventivnimi ukrepi, kot sta postopno povečevanje odmerka ali zmanjšanje odmerka, če je potrebno.
Venclyxto received a conditional marketing authorisation valid throughout the EU on 5 December 2016.
Za zdravilo Venclyxto je bilo 5. decembra 2016 izdano pogojno dovoljenje za promet, veljavno po vsej EU.
If the patient experiences certain side effects, treatment may be stopped temporarily or the dose reduced.
Če bolnik občuti določene neželene učinke, bo zdravljenje morda treba začasno prekiniti ali zmanjšati odmerek.
What measures are being taken to ensure the safe and effective use of Venclyxto?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Venclyxto?
Patients in this second study had all previously taken B-cell receptor pathway inhibitors.
Vsi bolniki v tej drugi študiji so predhodno prejemali zaviralce receptorske poti celic B.
This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines.
Ta beljakovina je v velikih količinah prisotna v rakavih celicah KLL, kjer celicam pripomore k daljšemu preživetju v telesu in jih naredi odporne proti zdravilom za zdravljenje raka.
The European Medicines Agency decided that Venclyxto's benefits outweigh its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da koristi zdravila Venclyxto odtehtajo njegova tveganja in da se lahko odobri za uporabo v EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Venclyxto have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Venclyxto upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
A high response rate was also seen in patients whose previous treatment with ibrutinib or idelalisib failed.
Poleg tega so visoko stopnjo odziva opazili tudi pri bolnikih, pri katerih je bilo predhodno zdravljenje z ibrutinibom ali idelalisibom neuspešno.
As for all medicines, data on the use of Venclyxto are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Venclyxto stalno spremljajo.
In these patients, Venclyxto is used when medicines known as B-cell receptor pathway inhibitors (ibrutinib and idelalisib) are not suitable or have failed.
Pri teh bolnikih se zdravilo Venclyxto uporablja, kadar zdravila, znana kot zaviralci receptorske poti celic B (ibrutinib in idelalisib), niso primerna ali niso bila uspešna.
Side effects reported with Venclyxto are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Venclyxto, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Why is Venclyxto authorised in the EU?
Zakaj je zdravilo Venclyxto odobreno v EU?
In another study of 127 patients with or without 17p deletion or TP53 mutation, the response rate was 70%.
V drugi študiji s 127 bolniki z delecijo 17p ali mutacijo TP53 ali brez njiju je bila stopnja odziva 70 %.
For more information about using Venclyxto, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Venclyxto glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
A high proportion of patients respond to Venclyxto after other treatments have failed or are unsuitable.
Na zdravilo Venclyxto se odzove velik delež bolnikov, kadar druga zdravila niso uspešna ali niso primerna.
When Venclyxto is used on its own, treatment should continue for as long as the patient improves or remains stable and the side effects are tolerable.
Kadar se zdravilo Venclixto uporablja samostojno, je treba zdravljenje nadaljevati tako dolgo, dokler se stanje bolnika izboljšuje oziroma ostaja stabilno in dokler so neželeni učinki znosni.
Venclyxto should be taken for 24 months from day 1 of the first cycle of rituximab.
Zdravilo Venclixto je treba jemati 24 mesecev od prvega dne v prvem ciklusu zdravljenja z rituksimabom.
In a main study of 107 previously treated patients with CLL and 17p deletion, 75% responded partially or completely to Venclyxto.
V glavni študiji s 107 predhodno zdravljenimi bolniki s KLL in delecijo 17p se jih je 75 % delno ali popolnoma odzvalo na zdravilo Venclyxto.
Venclyxto is available as tablets (10, 50 and 100 mg) to be taken by mouth once a day with a meal.
Zdravilo Venclyxto je na voljo v obliki tablet (10 mg, 50 mg in 100 mg), ki se jemljejo peroralno enkrat na dan med obrokom.
An overview of Venclyxto and why it is authorised in the EU
Pregled zdravila Venclyxto in zakaj je odobreno v EU
Venclyxto can be used in combination with rituximab (another cancer medicine) in patients who have received at least one previous treatment.
Zdravilo Venclyxto se lahko uporablja v kombinaciji z rituksimabom (drugim zdravilom za zdravljenje raka) pri bolnikih, ki so bili zdravljeni že vsaj enkrat.
What is Venclyxto and what is it used for?
Kaj je zdravilo Venclyxto in za kaj se uporablja?
By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down the progression of the disease.
Venetoklaks z vezavo na beljakovino Bcl-2 in zaviranjem njenega delovanja povzroči odmrtje rakavih celic in tako upočasni napredovanje bolezni.
• patients with particular genetic changes (17p deletion or TP53 mutation) that make them unsuitable for chemo-immunotherapy (a type of cancer treatment).
• bolnikih z določenimi genskimi spremembami (delecijo 17p ali mutacijo TP53), zaradi katerih niso primerni za kemoimunoterapijo (vrsta zdravljenja raka).
Venclyxto should be started and supervised by a doctor with experience of cancer medicines and can only be obtained with a prescription.
Zdravljenje z zdravilom Venclyxto mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravili za zdravljenje raka, predpisovanje in izdaja zdravila pa je le na recept.
• patients who do not have these genetic changes after treatments with chemo-immunotherapy and a B-cell receptor pathway inhibitor have both failed.
• bolnikih brez teh genskih sprememb, pri katerih zdravljenje s kemoimunoterapijo in zaviralcem receptorske poti celic B ni bilo uspešno.
Another study in 389 patients with CLL who received at least one previous treatment showed that patients treated with Venclyxto plus rituximab lived longer without their disease getting worse (progression-free survival) than patients treated with rituximab and bendamustine (another cancer medicine).
Druga študija s 389 vsaj enkrat predhodno zdravljenimi bolniki s KLL je pokazala, da je bilo ob zdravljenju z zdravilom Venclixto in rituksimabom obdobje brez bolezni ali brez njenega poslabšanja (podaljševanje časa preživetja brez napredovanja bolezni) daljše kot pri bolnikih, ki so se zdravili s rituksimabom in bendamustinom (drugo zdravilo proti raku).
Venclyxto must not be used with medicines known as ‘strong CYP3A inhibitors' during the early stages of treatment and must also not be used with St. John's wort (a herbal preparation used to treat anxiety and depression).
Zdravilo Venclyxto se v zgodnjih fazah zdravljenja ne sme uporabljati skupaj z zdravili, znanimi kot močni zaviralci CYP3A, in se prav tako ne sme uporabljati sočasno s šentjanževko (pripravkom rastlinskega izvora za zdravljenje anksioznosti in depresije).
The active substance in Venclyxto, venetoclax, attaches to a protein called Bcl-2.
Učinkovina v zdravilu Venclyxto, venetoklaks, se veže na beljakovino Bcl-2.
What are the risks associated with Venclyxto?
Kakšna tveganja so povezana z zdravilom Venclyxto?
What benefits of Venclyxto have been shown in studies?
Kakšne koristi je zdravilo Venclyxto izkazalo v študijah?
Venclyxto is a cancer medicine used to treat adults with a blood cancer known as chronic lymphocytic leukaemia (CLL).
Venclyxto je zdravilo za zdravljenje krvnega raka, znanega kot kronična limfocitna levkemija (KLL), pri odraslih bolnikih.
Studies have shown that a high proportion of patients have their cancer cells partially or completely cleared following treatment with Venclyxto on its own.
Študije so pokazale, da so rakave celice pri velikem deležu bolnikov po zdravljenju samo z zdravilom Venclyxto delno ali popolnoma izginile.
When used in combination with rituximab, Venclyxto was shown to prolong the time patients lived without their disease getting worse.
Zdravilo Venclixto v kombinaciji z rituksimabom je dokazano podaljšalo čas preživetja bolnikov brez napredovanja bolezni.
Other information about Venclyxto
Druge informacije o zdravilu Venclyxto:
The most common side effects with Venclyxto used on its own (seen in more than 1 in 5 people) are low levels of neutrophils (a type of white blood cell), diarrhoea, nausea, anaemia (low red blood cell counts), nose and throat infection and tiredness.
Najpogostejši neželeni učinki zdravila Venclyxto (ki so se pojavili pri več kot 1 bolniku od 5) so zmanjšano število nevtrofilcev (vrste belih krvnih celic), driska, navzea, anemija (nizke ravni rdečih krvnih celic), okužba nosu in grla ter utrujenost.
The most common serious side effects (seen in more than 2 in 100 people) in patients receiving Venclyxto in combination with rituximab or on its own are pneumonia (lung infection), fever associated with reduced neutrophils and tumour lysis syndrome (a complication caused by breakdown of cancer cells).
Najpogostejši resni neželeni učinki (ki so se pojavili pri več kot 2 bolnikih od 100) pri bolnikih, ki so se zdravili z zdravilom Venclyxto v kombinaciji z rituksimabom, so pljučnica (okužba pljuč), povišana telesna temperatura, povezana z znižanimi vrednostmi nevtrofilcev, in sindrom tumorske lize (zaplet, ki ga povzroča razgradnja rakavih celic).
Studies showed patients with particular genetic mutations (17p deletion or TP53 mutations) that make them unsuitable for chemo-immunotherapy responding well to Venclyxto used on its own.
Študije kažejo, da se bolniki z določenimi genskimi mutacijami (delecijo 17p ali mutacijami TP53), zaradi katerih so neprimerni za kemoimunoterapijo, na zdravljenje dobro odzovejo.
The most common side effects when Venclyxto is used with rituximab are low level of neutrophils, diarrhoea and nose and throat infection.
Najpogostejši neželeni učinki zdravila Venclyxto v kombinaciji s rituksimabom so zmanjšano število nevtrofilcev, driska ter okužba nosu in grla.
For the full list of side effects with Venclyxto, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Venclyxto, glejte navodilo za uporabo.
Venclyxto contains that active substance venetoclax.
Zdravilo Venclyxto vsebuje zdravilno učinkovino venetoklaks.
How is Venclyxto used?
Kako se zdravilo Venclyxto uporablja?
Patients should have taken Venclyxto at the daily dose of 400 mg for 7 days before starting therapy with rituximab.
Kadar se zdravilo Venclyxto uporablja v kombinaciji z rituksimabom, je priporočen odmerek tega zdravila 400 mg enkrat na dan. Bolniki naj bi sedem dni jemali 400-miligramski dnevni odmerek zdravilaVenclyxto, preden začnejo zdravljenje z rituksimabom.
How does Venclyxto work?
Kako zdravilo Venclyxto deluje?
Safety studies have shown that the strain is safe for turkeys.
Študije varnosti so pokazale, da je sev varen za purane.
For further information see the summary of product characteristics.
Za več informacij glejte povzetek glavnih značilnosti zdravila.
However, precautionary measures must be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.
Kljub temu je treba upoštevati previdnostne ukrepe, da se prepreči neposreden ali posreden stik med cepljenimi piščanci in purani.
The full EPAR for Vectormune ND can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila Vectormune ND je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
In the future if the animals are exposed to a similar virus and/or to a virus expressing a similar fusion protein, the immune system will be able to respond more quickly.
Če so živali pozneje izpostavljene podobnemu virusu in/ali virusu, ki izraža podoben fuzijski protein, se lahko imunski sistem nanj hitreje odzove.
This is a summary of the European public assessment report (EPAR) for Vectormune ND.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Vectormune ND.
The European Commission granted a marketing authorisation valid throughout the EU for Vectormune ND on 8 September 2015.
Evropska komisija je dovoljenje za promet z zdravilom Vectormune ND, veljavno po vsej Evropski uniji, izdala 8. septembra 2015.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Vectormune ND's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Vectormune ND večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The vaccine protects against a type of Marek disease virus that can cause visible infection.
Cepivo ščiti pred tisto vrsto virusa Marekove bolezni, ki lahko povzroči vidno okužbo.
As the vaccine is stored in liquid nitrogen, it is important that any handling is done by appropriately trained personnel in a well-ventilated area and that precautions are taken when preparing the vaccine.
Cepivo se shranjuje v tekočem dušiku, zato je pomembno, da z njim rokuje usposobljeno osebje v dobro prezračevanem prostoru in da se pri pripravi cepiva upoštevajo previdnostni ukrepi.
ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production.
Atipična kokošja kuga je virusna okužba pri piščancih, ki povzroča sopenje in kašelj, znake obolenja živcev (povešena krila, obračanje glave in vratu, kroženje in paralizo), otekanje tkiv okoli oči ter vratu, zelenkasto vodeno drisko in zmanjšano nesnost.
Two field studies were conducted in around 120,000 broiler chickens to evaluate the effects of the vaccine.
Za ocenjevanje učinkov cepiva so izvedli dve terenski študiji pri približno 120 000 pitovnih piščancih.
Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body.
Piščanci se okužijo v zgodnjem življenjskem obdobju z vdihavanjem prhljaja (delčkov odpadle kože), ki vsebuje virus, ki je lahko kužen še več mesecev po tem, ko odpade s telesa.
The withdrawal period for meat and eggs from chickens treated with Vectormune ND is ‘zero' days, which means that there is no mandatory waiting time.
Karenca za meso in jajca piščancev, zdravljenih z zdravilom Vectormune ND, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
The vaccine can be given to one-day-old chicks as a single injection under the skin or directly into 18-day-old eggs containing embryos (unhatched developing chicks).
Cepivo se lahko uporablja pri en dan starih piščancih v obliki enkratnega injiciranja pod kožo ali neposrednega injiciranja v 18 dni stara jajca, ki vsebujejo zarodke (še ne izvaljene piščance v razvoju).
Other information about Vectormune ND
Druge informacije o zdravilu Vectormune ND
Vectormune ND is available as a suspension and solvent to be made into a suspension for injection and can only be obtained with a prescription.
Zdravilo Vectormune ND je na voljo v obliki suspenzije in vehikla za pripravo suspenzije za injiciranje, njegovo predpisovanje in izdaja pa je le na recept.
When Vectormune ND is given to chickens or eggs, the animals' immune system recognises the virus as ‘foreign' and makes antibodies against it.
Ko piščance ali jajca cepimo s cepivom Vectormune ND, imunski sistem živali prepozna virus kot „tujek“ in začne proti njemu tvoriti protitelesa.
What are the risks associated with Vectormune ND?
Kakšna tveganja so povezana z zdravilom Vectormune ND?
What is Vectormune ND and what is it used for?
Kaj je zdravilo Vectormune ND in za kaj se uporablja?
Since no natural outbreaks of ND and MD occurred the chickens were challenged (exposed to infection) in the laboratory.
Ker ni bilo nobenega naravnega izbruha atipične kokošje kuge in Marekove bolezni, so piščance okužbi izpostavili v laboratoriju.
What benefits of Vectormune ND have been shown in studies?
Kakšne koristi je zdravilo Vectormune ND izkazalo v študijah?
For MD protection starts at one week of age and lasts for the risk period of infection with MD.
Zaščita proti Marekovi bolezni se razvije pri enem tednu starosti in traja celotno obdobje tveganja za okužbo z Marekovo boleznijo.
Since Vectormune ND is a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys.
Cepivo Vectormune ND je živo cepivo, zato se sev cepiva izloča iz cepljenih ptic in se lahko razširi na purane.
Why is Vectormune ND approved?
Zakaj je bilo zdravilo Vectormune ND odobreno?
Vectormune ND is a veterinary vaccine used to protect chickens against Newcastle disease (ND) and Marek's disease (MD).
Vectormune ND je cepivo za uporabo v veterinarski medicini, ki se uporablja za zaščito piščancev pred atipično kokošjo kugo (boleznijo Newcastle) in Marekovo boleznijo.
The active substance in Vectormune ND is a turkey herpesvirus (rHVT/ND) that does not cause disease in chickens and has been modified so that it also produces one of the proteins of a strain of Newcastle disease virus (D-26 lentogenic strain).
Zdravilna učinkovina v zdravilu Vectormune ND je puranji virus herpesa (rHVT/ND), ki ne povzroča bolezni pri piščancih in ki je bil spremenjen tako, da proizvaja tudi eno od beljakovin seva virusa bolezni Newcastle D 26 (lentogeni sev D-26).
MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs.
Marekova bolezen je okužba z virusom herpesa pri piščancih, ki lahko povzroči paralizo kril in nog ter nastanek tumorjev v različnih organih.
It is not intended to provide practical advice on how to use Vectormune ND.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Birds infected with MD virus can be carriers and shedders of the virus for life.
Ptice, okužene z virusom Marekove bolezni, so lahko prenašalke in raznašalke virusa celo življenje.
For ND protection starts at 3 weeks of age and lasts until 9 weeks of age for broilers (chickens bred for meat) and 18 weeks of age for layers (chickens bred for egg production).
Zaščita proti atipični kokošji kugi se pri pitovnih piščancih (piščancih za vzrejo mesa) razvije pri starosti treh tednov in traja do devetih tednov starosti, pri nesnicah (piščancih za proizvodnjo jajc) pa traja do 18. tedna starosti.
Newcastle disease and Marek's disease vaccine (live recombinant)
cepivo proti atipični kokošji kugi in Marekovi bolezni (živo, rekombinantno)
For practical information about using Vectormune ND, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za praktične informacije o uporabi zdravila Vectormune ND naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For more information about treatment with Vectormune ND, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za več informacij o zdravljenju z zdravilom Vectormune ND naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
The modified turkey herpesvirus in Vectormune ND is closely related to MD herpesvirus and will also produce the fusion protein which forms part of the outer coat of ND virus.
Spremenjeni puranji virus herpesa v cepivu Vectormune ND je zelo soroden virusu herpesa Marekove bolezni in bo ustvaril fuzijski protein, ki tvori del zunanje ovojnice virusa atipične kokošje kuge.
Twenty-two Vectormune ND vaccinated day-old layer chickens from this study were challenged at day 21 in the laboratory with ND strain and had no clinical signs for up to 2 weeks after challenge while all of 12 unvaccinated birds used for comparison died.
Na 21. dan študije so v laboratoriju sevu atipične kokošje kuge izpostavili 22 en dan starih nesnic, ki so bile v okviru študije cepljene s cepivom Vectormune ND, pri čemer se pri njih klinični znaki niso pokazali še najmanj dva tedna po izpostavitvi virusu, medtem ko je vseh 12 necepljenih ptic, ki so jih uporabili kot primerjalno skupino, umrlo.
Safety information has been included in the summary of product characteristics and the package leaflet for Vectormune ND, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
V povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
This will help protect the chickens against ND and MD.
To pomaga zaščititi piščance pred atipično kokošjo kugo in Marekovo boleznijo.
How does Vectormune ND work?
Kako zdravilo Vectormune ND deluje?
In a third field study around 10,000 one-day-old layer chickens were vaccinated with Vectormune ND and a similar number with a vaccine against ND alone.
V tretji terenski študiji je bilo s cepivom Vectormune ND cepljenih približno 10 000 en dan starih nesnic, podobno število pa je bilo cepljenih s cepivom samo proti atipični kokošji kugi.
How is Vectormune ND used?
Kako se zdravilo Vectormune ND uporablja?